Agios Pharmaceuticals (AGIO)
Commercializes mitapivat for rare blood disorders and develops additional hematology therapies.
$34.33
vs last close−0.64 (−1.83%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 110.61% | 66.04M shares | |
|---|---|---|---|
| 252 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.11% | 659.8K shares | |
| 16 holders · as of Aug 6, 2026 | |||
| Strategic holders | 11.93% | 7.12M shares | |
| 1 holder · as of Nov 14, 2019 | |||
| Adds to | 123.65% | ||
59.70M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 123.65%; nothing is left for Other.
13F, as of Jun 30, 2026
252 holders · 66.04M shares · 38 new positions · 135 increased · 66 reduced · 34 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 6.46M | 10.81% | +701.0K | Aug 7, 2026 |
| Farallon Capital Management LLC | 5.92M | 9.91% | +233.4K | Aug 14, 2026 |
| State Street Corp | 3.53M | 5.92% | +168.8K | Aug 7, 2026 |
| LYNX1 Capital Management LP | 3.41M | 5.71% | +797.4K | Aug 13, 2026 |
| D. E. Shaw & Co., Inc. | 3.11M | 5.20% | +425.8K | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 2.90M | 4.85% | +287.2K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 2.68M | 4.49% | +49.5K | Aug 13, 2026 |
| Armistice Capital, LLC | 2.40M | 4.02% | −316.0K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 7.80% | 4.51M | 13G | Jul 17, 2025 |
| State Street Corporation | 5.30% | 3.11M | 13G | Feb 9, 2026 |
| Vanguard Capital Management | 5.27% | 3.09M | 13G | Apr 29, 2026 |
| D. E. Shaw & Co., L.P. | 5.10% | 3.03M | 13G | Jul 2, 2026 |
| Lynx1 Capital Management LP | 5.10% | 3.01M | 13G | May 6, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 4, 2026 | Sarah Gheuensofficer: Chief Medical Officer | Sale | 30,000 | $30.48 | 54,645 |
| Jul 1, 2026 | Sarah Gheuensofficer: Chief Medical Officer | Sale | 4,007 | $37.56 | 84,645 |
| Apr 2, 2026 | Brian Goffdirector, officer: Chief Executive Officer | Sale · 2 lots | 19,068 | $34.71 | 177,604 |
| Apr 2, 2026 | Krishnan Viswanadhanofficer: Chief Corp Dev & Strategy | Sale | 2,959 | $34.71 | 10,282 |
| Apr 2, 2026 | Tsveta Milanovaofficer: Chief Commercial Officer | Sale | 3,262 | $34.71 | 46,829 |
| Apr 2, 2026 | Cecilia Jonesofficer: Chief Financial Officer | Sale | 3,141 | $34.71 | 54,998 |
| Apr 2, 2026 | Sarah Gheuensofficer: Chief Medical Officer | Sale | 2,940 | $34.71 | 80,277 |
| Apr 2, 2026 | James William Burnsofficer: Chief Legal Officer | Sale | 3,280 | $34.71 | 49,306 |
| Mar 5, 2026 | Krishnan Viswanadhanofficer: Chief Corp Dev & Strategy | Sale | 2,959 | $27.80 | 5,141 |
| Mar 3, 2026 | Theodore James Jr. Washburnofficer: Principal Accounting Officer | Sale | 5,272 | $28.88 | 868 |
House and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Rep. Gilbert Cisneros · CA31 | Purchase | $1,001 – $15,000 | Aug 20, 2026 | Sep 11, 2026 | |
| Rep. Gilbert Cisneros · CA31 | Purchase | $1,001 – $15,000 | Mar 3, 2026 | Apr 8, 2026 |